OBJECTIVE: To study the impact of occult hepatitis B virus (HBV) infection in 115 consecutive anti-HIV-positive, hepatitis B surface antigen-negative patients, naive for antiretroviral treatment. METHODS: Of these 115, 86 patients were followed for at least 6 months (range 6-36) with serial determinations of HIV RNA and HBV DNA by polymerase chain reaction and other laboratory tests. RESULTS: Of the 86 patients having a follow-up, plasma HBV DNA was detected in 17 (19.8%), 13 on admission and four during follow-up. HBV DNA was more frequently found in patients with isolated anti-hepatitis B core (HBc; 35.5% of 31 cases) than in those lacking anti-HBc and anti-hepatitis B surface (8.8% of 41, P < 0.005), or showing both (21.4% of 14). Twenty-eight patients (32.5%) experienced a hepatic flare during the follow-up; this event was more frequent in the 17 HBV-DNA-positive patients than in the 69 negative (64.7% versus 24.6%, P < 0.005). Of the 13 HBV-DNA-positive patients on admission, 11 receiving HAART containing lamivudine became HBV-DNA negative, but two of these again became positive and experienced a hepatic flare during treatment and two both during and after lamivudine treatment. A hepatic flare also occurred under lamivudine treatment in two of the four patients in whom HBV DNA became detectable during follow-up. The role of immune reconstitution inflammatory syndrome and HAART in inducing a hepatic flare was found to be marginal in 49 patients with no HBV or hepatitis C virus marker. CONCLUSION: The study suggests that HBV occult infection, relatively frequent in anti-HIV-positive patients, is associated with hepatic flares.
OBJECTIVE: To study the impact of occult hepatitis B virus (HBV) infection in 115 consecutive anti-HIV-positive, hepatitis B surface antigen-negative patients, naive for antiretroviral treatment. METHODS: Of these 115, 86 patients were followed for at least 6 months (range 6-36) with serial determinations of HIV RNA and HBV DNA by polymerase chain reaction and other laboratory tests. RESULTS: Of the 86 patients having a follow-up, plasma HBV DNA was detected in 17 (19.8%), 13 on admission and four during follow-up. HBV DNA was more frequently found in patients with isolated anti-hepatitis B core (HBc; 35.5% of 31 cases) than in those lacking anti-HBc and anti-hepatitis B surface (8.8% of 41, P < 0.005), or showing both (21.4% of 14). Twenty-eight patients (32.5%) experienced a hepatic flare during the follow-up; this event was more frequent in the 17 HBV-DNA-positive patients than in the 69 negative (64.7% versus 24.6%, P < 0.005). Of the 13 HBV-DNA-positive patients on admission, 11 receiving HAART containing lamivudine became HBV-DNA negative, but two of these again became positive and experienced a hepatic flare during treatment and two both during and after lamivudine treatment. A hepatic flare also occurred under lamivudine treatment in two of the four patients in whom HBV DNA became detectable during follow-up. The role of immune reconstitution inflammatory syndrome and HAART in inducing a hepatic flare was found to be marginal in 49 patients with no HBV or hepatitis C virus marker. CONCLUSION: The study suggests that HBV occult infection, relatively frequent in anti-HIV-positive patients, is associated with hepatic flares.
Authors: C S Coffin; P G Stock; L M Dove; C L Berg; N N Nissen; M P Curry; M Ragni; F G Regenstein; K E Sherman; M E Roland; N A Terrault Journal: Am J Transplant Date: 2010-03-19 Impact factor: 8.086
Authors: Patricia Price; David M Murdoch; Upasna Agarwal; Sharon R Lewin; Julian H Elliott; Martyn A French Journal: Clin Microbiol Rev Date: 2009-10 Impact factor: 26.132
Authors: Fabio Tramuto; Carmelo M Maida; Giuseppina M E Colomba; Paola Di Carlo; Giovanni Mazzola; Valentina Li Vecchi; Mario Affronti; Giuseppe Montalto; Francesco Vitale Journal: J Immigr Minor Health Date: 2013-08
Authors: G Morsica; F Ancarani; S Bagaglio; M Maracci; P Cicconi; A Cozzi Lepri; G Antonucci; R Bruno; T Santantonio; L Tacconi; F Baldelli; R Piscopo; D Santoro; A Lazzarin; A D'Arminio Monforte Journal: Infection Date: 2009-08-07 Impact factor: 3.553
Authors: Judith I Tsui; Audrey L French; Eric C Seaberg; Michael Augenbraun; Marek Nowicki; Marion Peters; Phyllis C Tien Journal: Clin Infect Dis Date: 2007-08-10 Impact factor: 9.079
Authors: Cynthia Firnhaber; Raquel Viana; Anne Reyneke; Doreen Schultze; Babatyi Malope; Mhairi Maskew; Adrian Di Bisceglie; Patrick MacPhail; Ian Sanne; Michael Kew Journal: Int J Infect Dis Date: 2008-12-09 Impact factor: 3.623